Abbas Walji

Company: Merck

Job title: Senior Director, Discovery Chemistry

Seminars:

Invention of MK-0616 – Merck’s Macrocyclic Peptide Oral PCSK9 Inhibitor 8:30 am

Highlighting the need for new modalities to drug challenging targets Elevating cyclic peptides as privileged scaffolds and a potential alternative to small molecules and large biopharmaceuticals Integrating various capabilities, including mRNA display and structure-based drug design, into drug discoveryRead more

day: Conference Day Two

Peptide Industry Leaders’ Panel Discussion – Is 2025 the Goldilocks Year for Peptide-Based Therapeutics? 8:20 am

This panel will discuss the key breakthroughs that have happened this year, the key challenges that have been overcome, and where the biggest excitement remains: Taking stock of the strengths, weaknesses, opportunities and threats (SWOT) for peptide-based therapeutics How do you perceive the peptide therapeutics space? How has this changed in the past 12 months?…Read more

day: Conference Day One